Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes

Tenofovir disoproxil fumarate (TDF) has been regarded as the most potent drug for treating patients with chronic hepatitis B (CHB). However recently, viral mutations associated with tenofovir have been reported. Here, we found a CHB patient with suboptimal response after more than 4 years of TDF treatment. Clonal analysis of hepatitis B virus (HBV) isolated from sequential sera of this patient identified the seven previously reported TDF-resistant mutations (CYELMVI). Interestingly, a threonine to alanine mutation at the 301 amino acid position of the reverse-transcriptase (RT) domain, (rtT301A), was commonly accompanied with CYELMVI at a high rate (72.7%). Since the rtT301A mutation has not been reported yet, we investigated the role of this naturally occurring mutation on the viral replication and susceptibility to tenofovir in various liver cells (hepatoma cells as well as primary human hepatocytes). A cell-based phenotypic assay revealed that the rtT301A mutation dramatically impaired the replication ability with meaningful reduction in sensitivity to tenofovir in hepatoma cell lines. However, attenuated viral replication by the rtT301A mutation was significantly restored in primary human hepatocytes (PHHs). Our findings suggest that the replication capability and drug sensitivity of HBV is different between hepatoma cell lines and PHHs. Therefore, our study emphasizes that validation studies should be performed not only in the liver cancer cell lines but also in the PHHs to understand the exact viral fitness under antiviral pressure in patients.

[1]  Ah Ram Lee,et al.  Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. , 2019, Journal of hepatology.

[2]  Xuesen Zhao,et al.  Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance , 2019, bioRxiv.

[3]  Haitao Guo,et al.  Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine‐resistant HBV isolate , 2019, Antiviral research.

[4]  J. H. Kim 2018 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis B: What's Different? , 2018, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[5]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[6]  T. Luedde,et al.  Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. , 2017, Journal of hepatology.

[7]  H. Chan,et al.  Tenofovir Alafenamide: A Review in Chronic Hepatitis B , 2017, Drugs.

[8]  John F. Flaherty,et al.  No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment , 2017, Journal of viral hepatitis.

[9]  Zhi-hui Xu,et al.  Increased Occurrence of Mutant rtI233V of HBV in Patients Receiving Adefovir Therapy , 2015, Antiviral therapy.

[10]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[11]  Gérard Krause,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[12]  Ah Ram Lee,et al.  Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance , 2015, PloS one.

[13]  H. Lee,et al.  Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial , 2015, Gut.

[14]  Jianming Hu,et al.  Unveiling the roles of HBV polymerase for new antiviral strategies. , 2015, Future virology.

[15]  H. Lee,et al.  Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial , 2015, Gut.

[16]  K. Kitrinos,et al.  No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  Young Youn Cho,et al.  Tenofovir Monotherapy versus Tenofovir plus Lamivudine or Telbivudine Combination Therapy in Treatment of Lamivudine-Resistant Chronic Hepatitis B , 2014, Antimicrobial Agents and Chemotherapy.

[18]  W. Choe,et al.  The Impact of the Hepatitis B Virus Polymerase rtA181T Mutation on Replication and Drug Resistance Is Potentially Affected by Overlapping Changes in Surface Gene , 2014, Journal of Virology.

[19]  P. Marcellin,et al.  Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load , 2013, Hepatology.

[20]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[21]  B. Seong,et al.  Discovery and Development of Anti-HBV Agents and Their Resistance , 2010, Molecules.

[22]  Ronald E. Rose,et al.  Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy , 2009, Hepatology.

[23]  M. Ghany,et al.  Antiviral resistance and hepatitis B therapy , 2009, Hepatology.

[24]  Seahee Kim,et al.  DDX3 DEAD-Box RNA Helicase Inhibits Hepatitis B Virus Reverse Transcription by Incorporation into Nucleocapsids , 2009, Journal of Virology.

[25]  Jianming Hu,et al.  Reverse Transcriptase- and RNA Packaging Signal-Dependent Incorporation of APOBEC3G into Hepatitis B Virus Nucleocapsids , 2008, Journal of Virology.

[26]  N. Warner,et al.  The L80I Substitution in the Reverse Transcriptase Domain of the Hepatitis B Virus Polymerase Is Associated with Lamivudine Resistance and Enhanced Viral Replication In Vitro , 2007, Antimicrobial Agents and Chemotherapy.

[27]  Angeline Bartholomeusz,et al.  HBV drug resistance: mechanisms, detection and interpretation. , 2006, Journal of hepatology.

[28]  J. Echevarría,et al.  Hepatitis B virus genetic diversity , 2006, Journal of medical virology.

[29]  D. Rowlands,et al.  Introduction of replication-competent hepatitis C virus transcripts using a tetracycline-regulable baculovirus delivery system. , 2004, The Journal of general virology.

[30]  Michael D. Miller,et al.  The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro , 2003, Journal of Virology.

[31]  Deborah Chavez,et al.  Antiviral Effect and Virus-Host Interactions in Response to Alpha Interferon, Gamma Interferon, Poly(I)-Poly(C), Tumor Necrosis Factor Alpha, and Ribavirin in Hepatitis C Virus Subgenomic Replicons , 2003, Journal of Virology.

[32]  Zheng-hong Yuan,et al.  A Single Amino Acid in the Reverse Transcriptase Domain of Hepatitis B Virus Affects Virus Replication Efficiency , 2001, Journal of Virology.

[33]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .

[34]  J. Wands,et al.  Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective , 1998, Hepatology.

[35]  C. Seeger,et al.  Hepadnavirus assembly and reverse transcription require a multi‐component chaperone complex which is incorporated into nucleocapsids , 1997, The EMBO journal.

[36]  J. Wands,et al.  Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication , 1991, Journal of virology.

[37]  P. Seglen Preparation of rat liver cells. 3. Enzymatic requirements for tissue dispersion. , 1973, Experimental cell research.